| Zacks Company Profile for Cyclacel Pharmaceuticals, Inc. (CYCC : NSDQ) |
|
|
| |
| • Company Description |
| CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.
Number of Employees: 6 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $8.23 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 3,799,795 shares |
| Shares Outstanding: 1.58 (millions) |
| Market Capitalization: $13.04 (millions) |
| Beta: 0.03 |
| 52 Week High: $477.60 |
| 52 Week Low: $3.08 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
62.65% |
54.47% |
| 12 Week |
-85.02% |
-86.95% |
| Year To Date |
-90.88% |
-91.48% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
LEVEL 10 TOWER 11 AVENUE 5 NO. 8 JALAN KERINCHI
-
KUALA LUMPUR,N8 592000
- |
ph: 908-517-7330
fax: 866-271-3466 |
ir@cyclacel.com |
http://www.cyclacel.com |
|
|
| |
| • General Corporate Information |
Officers
Doris Wong Sing Ee - Chief Executive Officer
Kiu Cu Seng - Chief Financial Officer and Secretary
Avraham Ben-Tzvi - Director
Kwang Fock Chong - Director
David Natan - Director
|
|
Peer Information
Cyclacel Pharmaceuticals, Inc. (CORR.)
Cyclacel Pharmaceuticals, Inc. (RSPI)
Cyclacel Pharmaceuticals, Inc. (CGXP)
Cyclacel Pharmaceuticals, Inc. (BGEN)
Cyclacel Pharmaceuticals, Inc. (GTBP)
Cyclacel Pharmaceuticals, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 23254L876
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/24
Next Expected EPS Date: 08/13/25
|
|
Share - Related Items
Shares Outstanding: 1.58
Most Recent Split Date: 7.00 (0.07:1)
Beta: 0.03
Market Capitalization: $13.04 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/13/25 |
|
|
|
| |
